Advancing Science. Improving Connections. Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal ...
People also ask
What happened to my Zynerba Pharmaceuticals stock?
What is the future of Zyne?
Who bought Zynerba Pharmaceuticals?
Should I accept Zynerba tender offer?
The Investor Relations website contains information about Harmony Biosciences's business for stockholders, potential investors, and financial analysts.
Oct 4, 2023 · In addition, these materials are available at no charge on the Enhanced SEC Filings section of the Investor Relations page of Zynerba's website ...
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical ...
Missing: investor relations
Aug 14, 2023 · The live and replay webcast of the call will be available on the investor relations page of our website at https://ir.harmonybiosciences.com/.
Investor Relations. NASDAQ: ZYXI. $12.15. $0.19 (1.59%). Currency in USD. Quote ... Sign up to receive updates on the latest investor events, reports, and news ...
ZYNE Earnings Call Transcripts ; Zynerba Pharmaceuticals (ZYNE) Investor Presentation - Slideshow · Fri, Sep. 16, 2022 ; Zynerba Pharmaceuticals (ZYNE) Investor ...
Missing: relations | Show results with:relations
ZYNE SEC Filings - Zynerba Pharmaceuticals Inc- Annual Report, Proxy Statement, Prospectus. ... investor presentations (found in 8Ks), insider trades (form 4) ...
Sep 27, 2023 · ("Zynerba") (Nasdaq: ZYNE) to 5:00 p.m., New York City time, on Tuesday, October 10, 2023, unless further extended. The tender offer was ...
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest ...